Form 4: Altimmune Director Sohn Acquires Stock Options

Catherine A. Sohn, a director at Altimmune, Inc., acquired 34,900 stock options on September 26, 2024, according to a Form 4 filing with the SEC.

Summary

• Catherine A. Sohn, a director of Altimmune, Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of 34,900 stock options on September 26, 2024.
• The exercise price of these options is $6.81.
• The options vest in equal monthly installments over 12 months following the grant date, contingent upon continued service.
• Sohn has granted power of attorney to Vipin K. Garg and Andrew Shutterly to handle SEC filings on her behalf.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director could be interpreted as a mildly positive signal, suggesting confidence in the company's prospects.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding Altimmune's future performance, but the vesting schedule of the options is contingent upon continued service.

Industry Context

This is a routine SEC filing related to insider transactions. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation packages.

Key Dates